Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedThe page’s interface/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a site release rather than any change to the underlying study or its details.SummaryDifference0.1%

- Check25 days agoChange Detected- Added Revision: v3.5.2. - Deleted Revision: v3.5.0.SummaryDifference0.1%

- Check53 days agoChange DetectedAdded revision: v3.5.0 and removed revision: v3.4.3 from the version history.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision history updated: added v3.4.3 and removed v3.4.2.SummaryDifference0.1%

- Check89 days agoChange DetectedA new revision v3.4.2 was added to the study record history, replacing the previous v3.4.1. This update is a metadata-level change and does not alter substantive study data or results.SummaryDifference0.1%

- Check96 days agoChange DetectedThe record history now shows a new revision v3.4.1 added and the previous v3.4.0 removed, reflecting a minor update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.